mRNA Vaccines in Cancer Treatment
DOI:
https://doi.org/10.61173/gs79x439Keywords:
mRNA vaccines, cancer treatment, personalized medicine, immunogenicity, manufacturing, ethical considerations, regulatory approval, solid tumors, melanomaAbstract
This article explores the groundbreaking application of mRNA vaccines in cancer treatment. It begins with an indepth examination of mRNA vaccines, elucidating their fundamental components and role in vaccine development. The discussion then pivots to transitioning mRNA vaccine technology into cancer therapy, highlighting potential advantages, such as personalized medicine, targeted therapy, and reduced side effects. Promising examples of mRNA vaccines in development for various cancer types, including melanoma and solid tumors, are discussed. However, it is crucial to acknowledge the challenges and limitations associated with this innovative approach, such as immunogenicity concerns, manufacturing scalability, ethical considerations, regulatory approval, and logistical hurdles. Despite these challenges, mRNA vaccines offer a transformative potential to revolutionize cancer therapy.
References
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646-674. Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P.
C., Makhene, M., Coler, R. N., ... & Beigel, J. H. (2020). An mRNA vaccine against SARS-CoV-2—preliminary report. New England Journal of Medicine, 383(20), 1920-1931. Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai,
C., Reuter, K. C., ... & Türeci, Ö. (2016). Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer Dean&Francis immunotherapy. Nature, 534(7607), 396-401. Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C.,
Reuter, K. C., ... & Türeci, Ö. (2020). Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature, 574(7780), 696-701. Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer,
M., Diekmann, J., ... & Türeci, Ö. (2020). Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature, 574(7780), 696-701.
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261-279.
Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics—developing a new class of drugs. Nature Reviews Drug Discovery, 13(10), 759-780. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M.,
Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer
statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249.
World Health Organization (WHO). (2021a). Cancer. https:// www.who.int/news-room/fact-sheets/detail/cancer
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
